Home Cart Sign in  
Chemical Structure| 1985605-59-1 Chemical Structure| 1985605-59-1

Structure of Baloxavir
CAS No.: 1985605-59-1

Chemical Structure| 1985605-59-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Baloxavir is a novel cap-dependent endonuclease (CEN) inhibitor used to treat influenza A and B virus infections. It exhibits strong antiviral activity by inhibiting viral RNA transcription and replication, aiding in improving flu treatment strategies.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Baloxavir

CAS No. :1985605-59-1
Formula : C24H19F2N3O4S
M.W : 483.49
SMILES Code : O=C1N2[C@](COCC2)([H])N([C@@H]3C4=CC=CC=C4SCC5=C(F)C(F)=CC=C35)N6C1=C(O)C(C=C6)=O
MDL No. :MFCD31619273
InChI Key :FIDLLEYNNRGVFR-CTNGQTDRSA-N
Pubchem ID :124081876

Safety of Baloxavir

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MDCK-SIAT1 cells 0.006 to 1.56 nM 24 h To evaluate the synergistic antiviral activity of Baloxavir and Oseltamivir. Results showed that Baloxavir and Oseltamivir had synergistic effects at low concentrations, even against viruses with reduced susceptibility to Baloxavir. mBio. 2022 Aug 30;13(4):e0105622.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Cynomolgus macaques H7N9 highly pathogenic avian influenza virus infection model Intragastric administration 1 mg/kg body weight Single dose on day 1 post-infection To evaluate the efficacy of Baloxavir against H7N9 highly pathogenic avian influenza virus in cynomolgus macaques. Results showed that virus titers in the Baloxavir group were significantly lower than in other treatment groups, and levels of IFN-α and IFN-β in plasma were higher. Antimicrob Agents Chemother. 2021 Feb 17;65(3):e01825-20

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.07mL

0.41mL

0.21mL

10.34mL

2.07mL

1.03mL

20.68mL

4.14mL

2.07mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories